

This week in therapeutics

| Indication | Target/marker/ pathway | Summary | Licensing status | Publication and contact information |
|---------------|---------------------------|--|----------------------------------|---|
| Cancer | | | | |
| Breast cancer | Aromatase | <p><i>In vitro</i> studies identified xanthone-based aromatase inhibitors that could help treat hormone-dependent breast cancer. Derivatives of the generic aromatase inhibitor xanthone showed greater inhibitory potency than the parent compound in a human placental microsome assay. Next steps include <i>in vivo</i> analysis of the compounds' biological activity. Marketed aromatase inhibitors for breast cancer include AstraZeneca plc's Arimidex anastrozole, Novartis AG's Femara letrozole and Pfizer Inc.'s Aromasin exemestane.</p> <p>SciBX 3(27); doi:10.1038/scibx.2010.819 Published online July 15, 2010</p> | Compounds unpatented; unlicensed | Gobbi, S. <i>et al.</i> <i>J. Med. Chem.</i> ; published online June 22, 2010; doi:10.1021/jm100319h Contact: Silvia Gobbi, University of Bologna, Bologna, Italy e-mail: silvia.gobbi@unibo.it |